• Something wrong with this record ?

Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome

K. Sloupenska, B. Koubkova, P. Horak, B. Hutyrova, M. Racansky, J. Mares, M. Miklusova, J. Schovanek, J. Zapletalova, M. Raska, M. Krupka

. 2023 ; 13 (2) : . [pub] 20230215

Status not-indexed Language English Country Switzerland

Document type Journal Article

Most patients suffering from Lyme disease are effectively treated with antibiotics. In some patients, however, problems persist for a long time despite appropriate therapy. The term post-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientific literature. The pathogenesis is still not precisely known, but the involvement of immunopathological mechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositis-specific (MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory proven history of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting the criteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoing differential diagnosis of neurological disorders without clinical and/or laboratory-proven history of Lyme disease. The presence of autoantibodies was determined by immunoblot methods and positive samples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence of myositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5% of control subjects exhibiting no evidence of Lyme disease history. The difference was statistically significant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positive subjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raised MSA/MAA autoantibodies formation in the group of PTLDS patients raising the question about their involvement in the pathogenesis of this syndrome.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002911
003      
CZ-PrNML
005      
20240717131233.0
007      
ta
008      
230413s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/life13020527 $2 doi
035    __
$a (PubMed)36836887
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Sloupenska, Kristyna $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000200605670
245    10
$a Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome / $c K. Sloupenska, B. Koubkova, P. Horak, B. Hutyrova, M. Racansky, J. Mares, M. Miklusova, J. Schovanek, J. Zapletalova, M. Raska, M. Krupka
520    9_
$a Most patients suffering from Lyme disease are effectively treated with antibiotics. In some patients, however, problems persist for a long time despite appropriate therapy. The term post-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientific literature. The pathogenesis is still not precisely known, but the involvement of immunopathological mechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositis-specific (MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory proven history of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting the criteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoing differential diagnosis of neurological disorders without clinical and/or laboratory-proven history of Lyme disease. The presence of autoantibodies was determined by immunoblot methods and positive samples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence of myositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5% of control subjects exhibiting no evidence of Lyme disease history. The difference was statistically significant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positive subjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raised MSA/MAA autoantibodies formation in the group of PTLDS patients raising the question about their involvement in the pathogenesis of this syndrome.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Koubková, Barbora $u Department of Allergology and Clinical Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic $7 xx0320139
700    1_
$a Horak, Pavel $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000022394064X $7 xx0032850
700    1_
$a Hutyrova, Beata $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $u Department of Allergology and Clinical Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
700    1_
$a Racansky, Mojmir $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $u Department of Allergology and Clinical Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
700    1_
$a Mares, Jan $u Department of Neurology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
700    1_
$a Miklusova, Martina $u Department of Neurology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
700    1_
$a Schovanek, Jan $u Third Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic
700    1_
$a Zapletalova, Jana $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic
700    1_
$a Raska, Milan $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $u Department of Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000285727246 $7 xx0060585
700    1_
$a Krupka, Michal $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000296997903 $7 xx0106791
773    0_
$w MED00186366 $t Life $x 2075-1729 $g Roč. 13, č. 2 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36836887 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20240717131228 $b ABA008
999    __
$a ok $b bmc $g 1922707 $s 1189118
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 13 $c 2 $e 20230215 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
LZP    __
$a Pubmed-20230413

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...